When in January 2026 the World Health Organization declared a new international emergency due to a hemorrhagic fever outbreak in Central Africa, early warning systems were already in place. It was not a surprise. Over the previous two years, networks of laboratories and genomic surveillance systems had multiplied their capacity to detect unknown pathogens before they crossed borders. The lesson from the covid-19 pandemic, though painful, had left a legacy: international cooperation in public health is no longer an option but a strategic necessity.
In 2025, global investment in epidemiological surveillance increased by 40% compared to 2020, according to World Bank data.
The new map of emerging diseases
Climate change and deforestation are pushing viruses to jump from animals to humans more frequently. In tropical and subtropical regions, the expansion of vectors like the Aedes mosquito has brought dengue and chikungunya to latitudes where they were once rare. But the real challenge is not just the emergence of new pathogens, but the capacity of health systems to respond without collapsing. Countries like Brazil, India, and Nigeria have strengthened their national laboratories, but huge inequalities persist in access to rapid tests and treatments.
Antimicrobial resistance
WHO considers antibiotic resistance one of the top ten threats to global public health. It could cause 10 million deaths per year by 2050 without coordinated action.
Access to medicines: the persistent gap
Despite advances in surveillance, equitable access to vaccines and treatments remains an Achilles' heel. During the 2026 emergency, high-income countries secured doses of experimental antivirals before poorer nations, repeating the pattern of the coronavirus pandemic. This time, however, there were differences: the World Trade Organization temporarily relaxed patents to allow local generic production in developing countries, a measure civil organizations had demanded for years.
The role of artificial intelligence and big data
Artificial intelligence has begun transforming epidemiology. Machine learning systems analyze real-time data streams from social media, drug sales, and medical consultations to anticipate outbreaks. In 2025, a model trained on human mobility data predicted a malaria peak in Southeast Asia two weeks in advance, allowing authorities to redistribute bed nets and antimalarials. However, reliance on big data also raises privacy and algorithmic bias risks, especially in countries with weak digital regulation.
Companies and states: a necessary alliance
Pharmaceutical and health technology companies have become central actors in the global response. The production of mRNA vaccines, which require ultra-cold chains, has driven investments in logistics and storage in developing countries. At the same time, the debate over contract transparency and pricing grows. Without clear regulation, public-private cooperation risks repeating old inequalities under a new guise.
What does this mean for the world?
Global public health has become a thermometer of international cooperation. Each outbreak, each epidemic, tests countries' willingness to share data, resources, and decisions. In a world where borders are porous for viruses but rigid for medicines, the future of health security depends on solidarity being more than a statement of intent—it must be concrete policy. The next emergency is not a matter of if, but when. And this time, the world says it is better prepared.